Abdalla EK, Vauthey JN. Focus on treatment of large hepatocellular carcinoma.
Ann Surg Oncol. 2004;11:1035-1036.
Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
Ann Surg. 2004;240:644-657.
Adrucil (fluorouracil injection) prescribing information. Available at:
http://www.sicor.com/products/pi/adrucil_6-2005_y36-102-103.pdf. Accessibility verified March 7, 2007.
American Cancer Society. Cancer Facts & Figures 2007. Available at:
http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp. Accessibility verified March 7, 2007.
Avastin (bevacizumab) prescribing information. Available at:
http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp. Accessibility verified March 7, 2007.
Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park). 2000;14:221-227.
Berber E, Ari E, Herceg N, et al. Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc.
2005;19:1613-1617.
Bleicher RJ, Allegra DP, Nora DT, et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol. 2003;10:52-58.
Bowles BJ, Machi J, Limm WM, et al. Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg. 2001;136:864-869.
Camptosar (irinotecan injection) prescribing information. Available at:
http://www.pfizer.com/pfizer/download/uspi_camptosar.pdf. Accessibility verified March 7, 2007.
Centers for Disease Control and Prevention and the Lance Armstrong Foundation. A National Action Plan for Cancer Survivorship: Advancing Public Health Strategies. Atlanta, Ga: Centers for Disease Control and Prevention, Division of Cancer Prevention and Control; 2004. Available at:
http://www.cdc.gov/cancer/survivorship/what_cdc_is_doing/action_plan.htm. Accessibility verified March 7, 2007.
Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Behavioral Risk Factor Surveillance System [CD-ROM] (1984-1995, 1998) and Public Use Data Tape (2004). 1997, 2000, 2005. Available at:
http://www.cdc.gov/brfss/about.htm. Accessibility verified March 7, 2007.
Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345
Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Ann Surg. 1999;230:1-8.
Curtiss CP, Haylock PJ, eds. AJN state of the science on cancer survivorship. Am J Nurs. 2006;106(3 suppl):1-102.
Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer. 2005;5:199-209.
de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol. 2000;175:1619-1625.
Eloxatin (oxaliplatin injection) prescribing information. Available at:
http://products.sanofi-aventis.us/eloxatin/eloxatin.html. Accessibility verified March 7, 2007.
Erbitux (cetuximab) prescribing information. Available at:
http://www.erbitux.com/erb/pdf/PI.pdf. Accessibility verified March 7, 2007.
Fernnandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-450.
Ferrell BR, Grant M, Hassey-Dow K.
Quality of life model applied to cancer survivors. Available at:
http://www.coh.org/prc/pdf/cancer_survivor_QOL.pdf.
Accessibility verified March 7, 2007.
Fong Y, Blumgart LH,
Fortner JG, et al. Pancreatic or liver resection for malignancy
is safe and effective for the elderly. Ann Surg.
1995;222:434-437.
Fong Y, Fortner J, Sun RL, et al. Clinical score
for predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg.
1999;230:309-321.
Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic
resection for metastatic colorectal cancer: analysis of clinical and
pathologic risk factors. Surgery. 1994;116:703-711.
Giantonio BJ, Catalano PJ, Meropol NJ, et al.
High-dose bevacizumab in combination with FOLFOX4 improves survival in
patients with previously treated advanced colorectal cancer: results
from the Eastern Cooperative Oncology Group (ECOG) study E3200.
Presented at: ASCO 2005 Gastrointestinal Cancers Symposium. Abstract
169a. Available at: http://www.asco.org. Accessibility verified March 7,
2007.
Goldberg RM, Rothenberg ML, Van Cutsem E, et al.
The continuum of care: a paradigm for the management of metastatic
colorectal cancer. Oncologist. 2007;12:38-50.
Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with
advanced colorectal cancer improves with the availability of
fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of
treatment. J Clin Oncol. 2004;22:1209-1214.
Grothey A, Sargent D. Overall survival of patients with advanced
colorectal cancer correlates with availability of fluorouracil,
irinotecan, and oxaliplatin regardless of whether doublet or
single-agent therapy is used first line. J Clin Oncol.
2005;23:9441-9442.
Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics,
trends, and multiple primary cancer analyses from the Surveillance,
Epidemiology, and End Results (SEER) program. Oncologist.
2007;12:20-37.
Hedrick EE, Hurwitz H, Sarkar S, et al. Post-progression therapy (PPT)
effect on survival in AVF2107, a phase III trial of bevacizumab in
first-line treatment of metastatic colorectal cancer (mCRC). J Clin
Oncol. 2004;22(suppl):249s. Abstract 3517.
Hewitt M, Ganz PA, rapporteurs. Implementing
Cancer Surviorship Care Planning: Workshop Summary. Washington, DC:
National Cancer Policy Board, Institute of Medicine of the National
Academies, National Academies Press; 2007. Available at:
http://www.nap.edu/catalog.php?record_id=11739.
Accessibility verified March 7, 2007.
Hewitt M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer
Survivor: Lost in Transition. Washington, DC: National Cancer Policy
Board, Institute of Medicine and National Research Council of the
National Academies, National Academies Press; 2006. Available at:
http://www.nap.edu/catalog.php?record_id=11468. Accessibility verified
March 7, 2007.
Hewitt M, Weiner SL, Simone JV, eds. Childhood Cancer Survivorship:
Improving Care and Quality of Life. Washington, DC: National Cancer
Policy Board, Institute of Medicine, National Research Council of the
National Academies, National Academies Press; 2003. Available at:
http://www.nap.edu/catalog.php?record_id=10767. Accessibility verified
March 7, 2007.
Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for
colorectal carcinoma metastases: a multi-institutional study of patterns
of recurrence. Surgery. 1986;100:278-284.
Hurwitz H. New combinations in metastatic colorectal cancer: what
are our expectations? Oncologist. 2005;10:320-322.
Jamison RL, Donohue JH, Nagorney
DM, et al. Hepatic resection for metastatic colorectal cancer
results in cure for some patients. Arch Surg. 1997;132:505-511.
Jemal A, Siegel R, Ward E, et al. Cancer
statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for
metastatic colorectal cancer. Am Surg.
1997;63:605-610.
Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or
oxaliplatin combined with leucovorin and 5-fluorouracil as first-line
treatment in advanced colorectal cancer: a multicenter, randomized,
phase II study. Ann Oncol. 2005;16:869-877.
Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer:
current options, current evidence. J Clin Oncol.
2005;23:4553-4560.
Kemeny N, Huang Y, Cohen AM, et al. Hepatic
arterial infusion of chemotherapy after resection of hepatic metastases
from colorectal cancer. N Engl J Med. 1999;341:2039-2048.
Kuderer NM, Crawford
J, Dale DC, Lyman GH. Mortality, morbidity, and cost associated
with febrile neutropenia in adult cancer patients. Cancer.
2006;106:2258-2266.
Leucovorin prescribing information. Available at:
http://www.bedfordlabs.com/products/inserts/LCV-P01.pdf.
Accessibility verified March 7, 2007.
Lichtman SM. Guidelines for the treatment of elderly cancer patients.
Cancer Control. 2003:10;445-453.
Mayer A, Takimoto M, Fritz E, et al. The
prognostic significance of proliferating cell nuclear antigen epidermal
growth factor receptor, and mdr gene expression in colorectal
cancer. Cancer. 1993;71:2454-2460.
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N
Engl J Med. 2005;352:476-487.
Mullan F. Seasons of survival: reflections of a physician with cancer.
N Engl J Med. 1985;313:270-273.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines
in Oncology: Colon Cancer—v.1.2007. Available at:
http://www.nccn.org/professionals/physician_gls/default.asp.
Accessibility verified March 7, 2007.
Nessim S. Can Survive: Reclaiming Your Life After Cancer. Boston,
Mass: Houghton Mifflin; 2000.
Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of
surgical margin status on survival and site of recurrence after hepatic
resection for colorectal metastases. Ann Surg. 2005;241:715-724.
Pin RH, Reinblatt M, Fong Y. Utilizing [alpha]-fetoprotein expression to
enhance oncolytic viral therapy in hepatocellular carcinoma. Ann Surg.
2004;240:659-666.
President’s Cancer Panel 2003-2004 Annual Report. Living Beyond
Cancer: Finding a New Balance. National Cancer Institute, National
Institutes of Health, US Dept of Health and Human Services; 2004.
Available at:
http://deainfo.nci.nih.gov/ADVISORY/pcp/pcp03-04rpt/Survivorship.pdf.
Accessibility verified March 7, 2007.
Ries LAG, Eisner MP, Kosary CL, et al, eds.
SEER Cancer Statistics Review, 1975-2000. Bethesda, Md: National
Cancer Institute. Available at:
http://seer.cancer.gov/csr/1975_2000.
Accessibility verified March 7, 2007.
Rossi S, Di Stasi M, Buscarini E, et al.
Percutaneous RF interstitial thermal ablation in the treatment of
hepatic cancer. AJR Am J Roentgenol.
1996;167:759-768.
Saltz LB, Clarke S, Diaz-Rubio, E, et al.
Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy
results from XELOX-1/NO16966, a randomized phase III trial in the
first-line treatment of metastatic colorectal cancer (MCRC). Presented
at: ASCO 2007 Gastrointestinal Cancers Symposium. Abstract 238.
Available at: http://www.asco.org. Accessibility verified March 7, 2007.
Saltz LB, Lenz H, Hochster, et al. Randomized phase II
trial of cetuximab/bevacizumab/irinotecan (CBI) versus
cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
J Clin Oncol. 2005;23(suppl, pt 1):248s. Abstract 3508.
Saltz LB. Metastatic colorectal cancer: is there one standard
approach? Oncology (Williston Park). 2005;19:1147-1153.
Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on
cancer management and decision making, part I. Cancer J.
2005;11:449-460.
Scheele J, Altendorf-Hofmann A, Grube T, et al.
Resection of colorectal liver metastases: what prognostic factors
determine patient selection [in German]? Chirurg.
2001;72:547-560.
Scheele J, Stang R,
Altendorf-Hofmann A, et al. Resection of colorectal liver
metastases. World J Surg. 1995;19:59-71.
Schwartz JB. Clinical pharmacology. In: Hazzard WR, Blass JP, Ettinger
WH, et al, eds. Principles of Geriatric Medicine and Gerontology.
4th ed. New York, NY: McGraw-Hill; 1999:303-331.
Siperstein A, Garland A, Engle K, et al. Local recurrence after
laparoscopic radiofrequency thermal ablation of hepatic tumors.
Ann Surg Oncol.
2000;7:106-113.
Solbiati L, Goldberg SN, Ierace T, et al. Hepatic metastases:
percutaneous radio-frequency ablation with cooled-tip electrodes.
Radiology. 1997;205:367-373.
Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency
ablation of hepatic metastases from colorectal cancer: long-term results
in 117 patients. Radiology. 2001;221:159-166.
Sun W, Haller DG. The Saltz article reviewed. Oncology (Williston
Park). 2005;19:1158-1160.
Venook A. Critical evaluation of current treatments in metastatic
colorectal cancer. Oncologist.
2005;10:250-261.
Vogelstein B, Kinzler KW. Colorectal tumors. In:
Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human
Cancer. 2nd ed. New York, NY: McGraw-Hill; 1998:565-587.
